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Abstract
The objective of this study was to evaluate structural damage progression based on clinical response in rheumatoid arthritis
patients with no or limited prior disease-modifying anti-rheumatic drug treatment receiving the Janus kinase (JAK)1/JAK2
inhibitor baricitinib 4 mg, methotrexate (MTX), or the combination. Data from the phase 3 RA-BEGIN study were analysed
post hoc. Proportions of patients with structural damage progression (change from baseline greater than the smallest detectable
change in modified total Sharp score) at week 52 were evaluated based on sustained Disease Activity Score for 28-joint count
with serum high-sensitivity C-reactive protein (DAS28-hsCRP) ≤ 3.2 or Simplified Disease Activity Index (SDAI) score ≤ 11; no
formal statistical comparisons between treatments were performed to test these proportions. Baseline factors associated with risk
of structural damage progression, including Clinical Disease Activity Index (CDAI) score, were identified using multivariate
analysis. Patients achieving versus not achieving sustained DAS28-hsCRP ≤ 3.2 or SDAI score ≤ 11 were less likely to expe-
rience structural damage progression at week 52. In patients achieving these responses, structural damage progression was less
likely with baricitinib monotherapy or plus MTX than with MTXmonotherapy. In patients not achieving these sustained clinical
thresholds, structural damage progression was less likely with baricitinib plus MTX than with either monotherapy. Independent
of treatment, baseline factors significantly associated with increased risk of structural damage progression included higher hsCRP
and CDAI score, smoking, female sex, and lower body mass index. In conclusion, patients achieving versus not achieving
sustained DAS28-hsCRP ≤ 3.2 or SDAI score ≤ 11 were less likely to show structural damage progression, irrespective of
treatment.
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Introduction
Rheumatoid arthritis (RA) is associated with progressive and
irreversible joint damage that starts early in the course of dis-
ease and can lead to disability [1]. It is one of the most impor-
tant reasons to diagnose and effectively treat RA as early as
possible, to prevent damage and subsequent functional limi-
tation. In RA, the joint synovium becomes infiltrated with
immune cells as a result of a dysregulated immune response
[2]. These cells overproduce pro-inflammatory cytokines,
such as interleukins, tumour necrosis factor, interferons, vari-
ous growth factors, granulocyte and macrophage colony-
stimulating factors, and chemokines (chemotactic cytokines)
[3], which attract further inflammatory and immune cells and
stimulate them to release products that cause joint destruction
[4]. Consequently, research into new therapies for RA has
focused on the targeted blockade of cytokine intracellular sig-
nal transduction pathways, such as those involving Janus ki-
nases (JAKs) [5].
Baricitinib is an oral selective inhibitor of JAK1 and JAK2
with less effect on JAK3 and tyrosine kinase 2 [6]. It has been
approved in more than 40 countries, including European
countries, Japan, and, recently, the USA (2 mg only), at doses
of 4 or 2 mg once daily as monotherapy or in combination
with methotrexate (MTX) in adults with moderate to severe
RAwho do not respond adequately or are intolerant to one or
more disease-modifying anti-rheumatic drugs (DMARDs) [7,
8]. The efficacy and safety of baricitinib as a treatment for RA
were established in four phase 3, randomised, double-blind,
multicentre studies in patients with active disease [9–12]. RA-
BEGIN was a phase 3, 52-week, double-blind, three-arm,
multicentre study assessing the efficacy and safety of oral
baricitinib 4 mg once daily as monotherapy or in combination
with MTX versus MTX monotherapy in patients with active
RA who had no or limited prior DMARD treatment
(NCT01711359 [9]). MTX monotherapy, given at a dose of
up to 20mg/week, was the active comparator. Baricitinib 4mg
once daily as monotherapy or in combination with MTX was
associated with significant improvements in the signs and
symptoms of RA, physical function, and patient-reported out-
comes compared to MTX monotherapy. In addition, com-
pared to MTX, structural damage progression was reduced
in both baricitinib groups; the difference was statistically sig-
nificant only for the baricitinib plusMTX group. Further anal-
yses were performed to clarify the effectiveness of baricitinib
monotherapy with respect to structural damage progression.
This paper reports the results from post hoc analyses con-
ducted using data from the RA-BEGIN study to estimate the
proportion of patients with structural damage progression in
each treatment group stratified by treatment response (mea-
sured using the Disease Activity Score for 28-joint count
[DAS28] based on serum high-sensitivity C-reactive protein
[hsCRP], DAS28-hsCRP, and the Simplified Disease Activity
Index [SDAI]) and to identify baseline factors, including the
Clinical Disease Activity Index (CDAI) score, associated with
the risk of structural damage progression at week 52.
Methods
Patients
Data from patients in the modified intent-to-treat (mITT)
population of RA-BEGIN [5] who had both baseline and
post-baseline radiographic data were evaluated. Patients
aged ≥ 18 years with active RA who had received no or
limited treatment with conventional synthetic DMARDs
(up to three weekly doses of MTX allowed) and no treat-
ment with biologic DMARDs were randomised to MTX
once weekly (n = 210), baricitinib 4 mg once daily (n =
159) or a combination of baricitinib 4 mg once daily and
MTX once weekly (n = 215) for 52 weeks. Treatment with
MTX was initiated at a dose of 10 mg/week and, if toler-
ated, increased to 20 mg/week by week 8; a lower dose of
MTX was allowed if necessary because of toxicity or at the
investigator’s decision. Additional key inclusion criteria were
positive anti-cyclic citrullinated peptide antibody (ACPA) >
10 U/mL or rheumatoid factor (RF) > 14 U/mL; ≥ 6/68 tender
joints; ≥ 6/66 swollen joints; and hsCRP ≥ 1.2 × upper limit of
normal (≥ 3.6 mg/L; normal < 3 mg/L).
Radiographs
Structural joint damage was measured with radiographs of
the hands and feet performed within 4 weeks prior to base-
line and at weeks 12, 24, and 52, or at the last visit in the
event of early study termination. Joint damage was mea-
sured using the van der Heijde-modified total Sharp score
(mTSS) [13, 14]. Radiographs were scored centrally and
independently by two readers who were blinded to the
chronological order of the radiographs, patient identifiers,
and treatment groups, with adjudication by a third reader if
there was disagreement beyond a predefined level. The
mean score from the two readers was used unless the ad-
judicator provided a score, in which case the two scores in
closest agreement were used.
Data for mTSS at week 52 were imputed using linear
extrapolation for patients who discontinued the study be-
fore week 52, had missing data, or received rescue therapy
at week 24 (or any time thereafter). Linear extrapolation
used baseline data and the most recent radiographic data
before discontinuation, the missed radiograph, or initiation
of rescue therapy. Missing post-baseline values were im-
puted only if a baseline value and a post-baseline value
from week 12 onwards were available, and the patient
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was receiving the same treatment at each applicable time
point.
Structural damage progression
Structural damage progression was defined as change from
baseline greater than the smallest detectable change (SDC)
in mTSS at week 52. The SDC is the minimum amount of
change in a patient’s score that can be assessed beyond mea-
surement error. It was calculated according to the method of
Bruynesteyn et al. [15]. The SDC in mTSS in the RA-BEGIN
study at week 52 was 1.4.
Treatment response
Treatment response was measured using the DAS28-
hsCRP and the SDAI. Patients were classified into two
groups based on their DAS28-hsCRP response: patients
in DAS28-group A had a sustained DAS28-hsCRP of ≤
3.2 at weeks 16, 20, and 24, whereas patients in DAS28-
group B had a DAS28-hsCRP of > 3.2 or missing data at
any of weeks 16, 20, and 24. The cut-off value of ≤ 3.2 for
DAS28-hsCRP was selected when the study protocol was
initially designed and before it was understood that low
disease activity (LDA) according to DAS28(CRP) is actu-
ally lower than 3.2 [16, 17]. For this reason, we do not
refer to the value of DAS28-hsCRP < 3.2 as LDA.
Supportive analyses were also performed, in which pa-
tients were classified into two groups based on SDAI re-
sponse: patients in SDAI-group A had a sustained SDAI
score of ≤ 11 at weeks 16, 20, and 24, whereas patients in
SDAI-group B had an SDAI score of > 11 or missing data
at any of weeks 16, 20, and 24. The cut-off value of ≤ 11
for SDAI was that recommended by the ACR [18, 19] and
EULAR [20, 21] for defining LDA.
Graphical displays (heatmaps) were produced to show
individual patient DAS28-hsCRP and SDAI values (by
rows) at each visit (by columns) for the different treat-
ments and response groups. These displays use different
colours to indicate different response categories: DAS28-
hsCRP ≤ 2.6, > 2.6 to ≤ 3.2, > 3.2 to ≤ 5.1, or > 5.1, and
SDAI remission, or low, moderate, or high disease
activity.
Analyses
Baseline patient demographic characteristics were grouped
by response to treatment (DAS28-group A vs DAS28-
group B; SDAI-group A vs SDAI-group B). To estimate
the response to treatment, odds ratios (ORs) with the cor-
responding 95% confidence intervals (CI) and p values for
the likelihood of a sustained DAS28-hsCRP of ≤ 3.2 or
SDAI score ≤ 11 were calculated using a logistic regression
model including treatment group and adjusted for the two
stratification factors used at randomisation: region + base-
line joint erosion status.
To determine the effect of treatment on structural damage
progression, ORs (with corresponding 95% CIs and p values)
for the likelihood of structural damage progression were cal-
culated using a logistic regression model including treatment
group and adjusted for the same two stratification factors used
at randomisation.
Structural damage progression according
to treatment response
Observed and adjusted proportions of patients in each treat-
ment arm with change from baseline in mTSS > SDC at week
52 were determined for the defined response groups. No for-
mal statistical comparisons were performed between treat-
ments with respect to the proportion of patients with structural
damage progression based on treatment response.
Adjusted (least squares [LS] means) estimates of the pro-
portions of patients with change in mTSS > SDC at week 52
were obtained using a multivariate logistic model including
the following factors: treatment, response to treatment, age
(years), sex, body mass index (BMI), RA duration from diag-
nosis (years), smoker (yes/no), baseline ACPA (> 10 U/mL
positive), baseline RF (> 14 IU/mL positive), baseline
hsCRP, presence of radiographic erosions at baseline (yes/
no, 0 vs > 0), baseline mTSS, baseline disease status
(DAS28-hsCRP or SDAI in the analyses for DAS28-hsCRP
and SDAI, respectively), baseline Health Assessment
Questionnaire-Disability Index (HAQ-DI) score, geographic
location, and treatment-by-response to treatment interaction.
Adjusted (LS) means were estimated from the multivariate
logistic regression model with continuous covariates fixed at
their mean values and categorical covariates fixed at their
proportional distribution in the data. Patients with missing
data for the covariates used in the model were excluded from
multivariate analyses.
Baseline factors associated with structural damage
progression
Associations between baseline factors and structural damage
progression were also assessed using a multivariate logistic
regression model including the same covariates as in the mod-
el above, excluding response to treatment and treatment-by-
response to treatment interaction. In addition, to assess wheth-
er baseline disease status was associated with structural pro-
gression, the CDAI score was included in the model; this score
was used because hsCRP was also included. Patients with
missing data for the covariates used in the model were exclud-
ed from multivariate analyses.
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Data availability The data that support the findings of this
study are available from Eli Lilly and Company but restric-
tions apply to the availability of these data.
Results
Structural damage progression
Of the 584 patients in the mITT population of RA-BEGIN,
545 had radiographic data. Data from 39 patients with
completely missing radiographic data were excluded from
analyses (18 in the MTX group, 5 in the baricitinib monother-
apy group, and 16 in the combination therapy group). All of
the patients with missing radiographic data would have been
classified in DAS28- or SDAI-group B apart from one patient
receiving baricitinib monotherapy. According to the study
protocol, up to three doses of MTX were allowed prior to
randomisation; no other previous conventional synthetic
DMARDs were allowed. Few of the 584 patients in the
mITT population of RA-BEGIN had prior limited exposure
to conventional synthetic DMARDs (20/210 in the MTX
group, 13/159 in the baricitinib monotherapy group, and 18/
215 in the combination therapy group). Of these patients, only
one in the MTX group and one in the combination therapy
group had missing radiographic data. Of the 545 patients with
radiographic data, 85 (15.6%) had a change from baseline in
mTSS > SDC at week 52: 21.9% (42/192) of MTX-treated
patients, 14.9% (23/154) of baricitinib monotherapy-treated
patients, and 10.1% (20/199) of baricitinib plus MTX-
treated patients.
ORs for the likelihood of structural damage progression
were 0.62 (95% CI 0.35, 1.09) for baricitinib monotherapy
versus MTX and 0.39 (95% CI 0.22, 0.70) for baricitinib plus
MTX versus MTX.
Treatment response based on DAS28-hsCRP
A total of 212 patients were classified in DAS28-group A and
372 in DAS28-group B. Baseline characteristics of these pa-
tient groups are shown in Table 1. Heatmap plots showing
individual responses to treatment over time in the two
DAS28-hsCRP groups are presented in Online Resource 1.
ORs for a sustained DAS28-hsCRP ≤ 3.2 were 2.8 (95% CI
1.7, 4.4) for baricitinib monotherapy versus MTX and 3.3
(95% CI 2.2, 5.1) for baricitinib plus MTX versus MTX.
Structural damage progression based on achieving
DAS28-hsCRP ≤ 3.2
Across treatment groups, smaller proportions of patients who
achieved sustained DAS28-hsCRP ≤ 3.2 (DAS28-group A)
had structural damage progression at week 52 than patients
who did not achieve sustained DAS28-hsCRP ≤ 3.2 (DAS28-
group B) (Fig. 1a). The proportion of patients with structural
damage progression was lower in the groups with sustained
DAS28-hsCRP ≤ 3.2 with baricitinib, either as monotherapy
or in combination with MTX, than in the group who achieved
sustained DAS28-hsCRP ≤ 3.2 with MTX alone. In patients
who did not achieve sustained DAS28-hsCRP ≤ 3.2, structural
damage progression was less frequent with combination ther-
apy than with baricitinib monotherapy or MTX monotherapy.
After controlling for potential imbalances with respect to
baseline factors that might act as confounders, estimated ad-
justed (LS) means for the proportions of patients with struc-
tural damage progression in DAS28-groups A and B followed
a similar pattern to that observed with no adjustment (Fig. 1b).
The only comparisons that showed a significantly reduced risk
of structural progression were for patients responding to
baricitinib monotherapy versus those not responding to
baricitinib monotherapy (OR 0.32; 95% CI 0.11, 0.99; p =
0.048) and for patients not responding to baricitinib plus
MTX versus those not responding to MTX (OR 0.44; 95%
CI 0.21, 0.92; p = 0.030) (Table 2).
Treatment response based on SDAI
When classified by whether or not patients achieved a
sustained SDAI score of ≤ 11, 209 patients were included in
SDAI-group A and 375 in SDAI-group B. Baseline character-
istics of these patients were similar to those of patients
grouped according to whether or not they achieved DAS28-
hsCRP ≤ 3.2 (Online Resource 2). Heatmap plots showing
individual responses to treatment in the two SDAI groups
are presented in Online Resource 3. ORs for a sustained
SDAI ≤ 11 were 1.9 (95% CI 1.2, 3.0) for baricitinib versus
MTX and 2.4 (95% CI 1.6, 3.6) for baricitinib plus MTX
versus MTX.
Structural damage progression based on achieving
SDAI ≤ 11
Structural damage progression results based on achieving a
sustained SDAI score of ≤ 11 were similar to those observed
based on achieving DAS28-hsCRP ≤ 3.2 (Fig. 2a). After con-
trolling for potential imbalances with respect to baseline fac-
tors that might act as confounders, estimated adjusted (LS)
means for the proportions of patients with structural damage
progression in SDAI-groups A and B followed a similar pat-
tern to that observed with no adjustment (Fig. 2b). The only
comparisons that showed a significantly reduced risk of struc-
tural damage progression were for patients responding to
baricitinib plus MTX versus those responding to MTX (OR
0.25; 95% CI 0.08, 0.80; p = 0.019) and for patients not
responding to baricitinib plus MTX versus those not
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responding to MTX (OR 0.42; 95% CI 0.20, 0.89; p = 0.024)
(Table 2).
Baseline factors associated with structural damage
progression
Baseline factors showing a statistically significant associa-
tion with an increased risk of structural damage progression
were higher hsCRP, higher CDAI score, female sex,
smoking, and lower BMI (Table 3). The estimated OR for
baseline hsCRP was 1.02 (p < 0.001), meaning the odds of
structural damage progression increased by a factor of 1.02
when baseline hsCRP increased by one unit and other vari-
ables remained fixed (Fig. 3a). The estimated OR for base-
line CDAI score was 1.03 (p = 0.038), meaning the odds of
structural damage progression increased by a factor of 1.03
when baseline CDAI score increased by one unit and other
variables remained fixed (Fig. 3b). The estimated OR for
baseline BMI was 0.94 (p = 0.025), meaning the odds of
structural damage progression changed by a factor of 0.94
when baseline BMI increased by one unit and other variables
remained fixed (Fig. 3c).
Discussion
The results of analyses from the phase 3 RA-BEGIN study
showed that approximately 40% of patients with active RA
and no or limited prior DMARD treatment achieved a
sustained DAS28-hsCRP ≤ 3.2 or SDAI score ≤ 11 with
baricitinib monotherapy 4 mg or baricitinib 4 mg plus MTX,
as demonstrated in heatmaps of individual patient responses.
Most of these patients achieved DAS28-hsCRP < 2.6 after
16–24 weeks. Patients were less likely to experience structural
damage progression at week 52 if they achieved a sustained
DAS28-hsCRP ≤ 3.2 or SDAI score ≤ 11 during the first
6 months of treatment (at weeks 16, 20, and 24), and in such
patients, baricitinib 4 mg given as monotherapy or in combi-
nation with MTXwas more effective thanMTXmonotherapy
at reducing the risk of structural progression.
A cut-off value of < 3.2 for DAS28(CRP) was previously
recommended by the ACR [18] and was also commonly used
in clinical practice, clinical trials, and research publications
[22–25] for differentiating LDA from moderate or more se-
vere disease activity. However, it has become apparent over
recent years that the values for remission and LDA as defined
using DAS28 based on erythrocyte sedimentation rate (< 2.6
Table 1 Patient baseline characteristics grouped by DAS28-hsCRP and treatment
DAS28-Group A (N = 212) DAS28-Group B (N = 372)
Treatment (N; %
of treatment group)
MTX (N = 45;
21.4%)
Bari (N = 67;
42.1%)
Bari + MTX
(N = 100;
46.5%)
MTX (N = 165;
78.6%)
Bari (N = 92;
57.9%)
Bari + MTX
(N = 115;
53.5%)
Age, (years) 52 ± 14 52 ± 13 46 ± 14 50 ± 13 50 ± 13 51 ± 13
Female 31 (68.9) 49 (73.1) 71 (71.0) 117 (70.9) 72 (78.3) 85 (73.9)
BMI, (kg/m2) 25.1 ± 5.1 27.5 ± 7.3 25.2 ± 5.1 26.9 ± 6.4 26.4 ± 6.1 27.8 ± 6.4
Smoker 7 (15.6) 16 (23.9) 21 (21.0) 41 (24.8) 21 (22.8) 26 (22.6)
Duration of RA
from diagnosis,
(years)a
0.2 (0.1, 0.3) 0.2 (0.1, 0.5) 0.2 (0.1, 1.0) 0.2 (0.1, 0.7) 0.4 (0.1, 1.4) 0.3 (0.1, 1.0)
ACPA positiveb 41 (91.1) 63 (94.0) 94 (94.0) 152 (92.7) 79 (85.9) 98 (85.2)
RF positivec 43 (95.6) 67 (100.0) 94 (94.0) 160 (97.0) 88 (95.7) 110 (95.7)
≥ 1 joint erosion 28 (62.2) 43 (64.2) 60 (60.0) 110 (67.1) 62 (67.4) 77 (67.0)
hsCRP (mg/L) 14.5 ± 10.8 20.5 ± 19.7 25.2 ± 27.5 24.5 ± 23.5 26.1 ± 30.0 23.5 ± 31.1
DAS28-hsCRP 5.5 ± 0.9 5.7 ± 0.9 5.8 ± 1.0 5.9 ± 1.0 6.1 ± 1.0 6.0 ± 0.9
SDAI 37.7 ± 12.6 38.6 ± 12.0 40.0 ± 13.2 42.7 ± 14.1 45.6 ± 14.6 45.2 ± 13.0
mTSS 10.2 ± 23.5 11.8 ± 28.5 9.7 ± 17.5 12.3 ± 21.8 14.4 ± 26.0 13.1 ± 22.3
HAQ-DI total score 1.5 ± 0.7 1.6 ± 0.7 1.5 ± 0.7 1.7 ± 0.7 1.7 ± 0.7 1.6 ± 0.6
Data are reported as mean ± standard deviation or n (%) unless otherwise indicated. DAS28-group A: sustained DAS28-hsCRP ≤ 3.2 at weeks 16, 20,
and 24; DAS28-group B: DAS28-hsCRP > 3.2 or missing data at any of weeks 16, 20, and 24
aData presented as medians with interquartile range
bACPA positive (> ULN [ULN= 10 U/mL])
c RF positive (> ULN [ULN = 14 U/mL])
ACPA anti-cyclic citrullinated peptide antibody, Bari baricitinib, DAS28 Disease Activity Score for 28-joint counts, BMI body mass index, HAQ-DI
Health Assessment Questionnaire-Disability Index, hsCRP high-sensitivity C-reactive protein, mTSS van der Heijde-modified total Sharp score, MTX
methotrexate, RA rheumatoid arthritis, RF rheumatoid factor, SDAI Simplified Disease Activity Index, ULN upper limit of normal
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and < 3.2, respectively) are not accurate for DAS28(CRP).
The cut-off value of ≤ 3.2 for DAS28-hsCRP in this study
was selected when the protocol was initially designed, before
it was understood that LDA according to DAS28(CRP) is
actually lower than 3.2 [16, 17]. The cut-off value of ≤ 11
for SDAI was that recommended by the ACR [18, 19] and
EULAR [20, 21] for defining LDA. It is important to note that,
although achievingDAS28-hsCRP ≤ 3.2 or an SDAI score ≤ 11
was used as the cut off, we are not suggesting that this should
be the treatment target, especially in patients who have previ-
ously received minimal treatment for RA. As recommended
by EULAR and the ACR, the primary treatment target should
be remission, with low disease activity being the target only if
achieving remission is not feasible, using either Boolean remis-
sion or SDAI score ≤ 3.3 [19, 20]. The results of these post
hoc analyses suggest that patients achieving DAS28-hsCRP
≤ 3.2 or a SDAI score ≤ 11 are less likely to have structural
damage progression than patients who do not achieve these
Fig. 1 a Observed and b adjusted proportions of patients with structural
damage progression (CFB in mTSS > SDC) at week 52 in DAS28-group
A (sustained DAS28-hsCRP ≤ 3.2 at weeks 16, 20, and 24) and DAS28-
group B (DAS28-hsCRP > 3.2 or missing data at any of weeks 16, 20,
and 24). Adjusted proportions (LS means) were estimated using a multi-
variate logistic regression model (41 patients were excluded due to
missing data for covariates used in the model). Bari baricitinib, CFB
change from baseline, DAS28-hsCRP Disease Activity Score for 28-
joint counts based on high-sensitivity C-reactive protein, LS least squares,
mTSS van der Heijde-modified total Sharp score, MTX methotrexate,
SDC smallest detectable change (1.4 in the RA-BEGIN-modified
intent-to-treat population)
Table 2 Odds of structural damage progression based on DAS28-hsCRP and SDAI score with treatment
DAS28-hsCRP ≤ 3.2 SDAI score ≤ 11
Odds ratio (95% CI) p value Odds ratio (95% CI) p value
In patients who achieved a sustained outcome
Baricitinib 4 mg vs MTX 0.46 (0.12, 1.71) 0.247 0.42 (0.13, 1.35) 0.145
Baricitinib 4 mg + MTX vs MTX 0.32 (0.09, 1.12) 0.076 0.25 (0.08, 0.80) 0.019
In patients who did not achieve a sustained outcome
Baricitinib 4 mg vs MTX 0.72 (0.36, 1.45) 0.356 0.70 (0.34, 1.43) 0.327
Baricitinib 4 mg + MTX vs MTX 0.44 (0.21, 0.92) 0.030 0.42 (0.20, 0.89) 0.024
In all patients
MTX (sustained outcome: yes vs no) 0.51 (0.18, 1.41) 0.192 0.79 (0.33, 1.90) 0.604
Baricitinib 4 mg (sustained outcome: yes vs no) 0.32 (0.11, 0.99) 0.048 0.48 (0.16, 1.39) 0.176
Baricitinib 4 mg + MTX (sustained outcome: yes vs no) 0.38 (0.13, 1.06) 0.065 0.48 (0.17, 1.35) 0.166
Odds ratios were estimated using a multivariate logistic regression model adjusted for baseline factors. Comparisons significantly associated with a
decreased risk of structural damage progression are shown in bold
DAS28-hsCRPDisease Activity Score for 28-joint counts based on high-sensitivity C-reactive protein,CI confidence interval,MTXmethotrexate, SDAI
Simplified Disease Activity Index
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targets, suggesting that lower disease activity is important to
preserve structural integrity.
Identification of baseline factors associated with an in-
creased risk of structural damage progression in patients initi-
ating therapy may help clinicians to identify those who might
be at greatest risk. Baseline factors identified in the current
study included higher hsCRP, a higher CDAI score, smoking,
lower BMI, and female sex, suggesting that male patients and
non-smokers are at lower risk of structural damage progres-
sion than female patients and smokers. This is in line with the
Fig. 2 a Observed and b adjusted proportions of patients with structural
damage progression (CFB in mTSS > SDC) at week 52 in SDAI-group A
(sustained SDAI score ≤ 11 at weeks 16, 20, and 24) and SDAI-group B
(SDAI score > 11 or missing data at any of weeks 16, 20, and 24).
Adjusted proportions (LS means) were estimated using a multivariate
logistic regression model (47 patients were excluded due to missing data
for covariates used in the model). Bari baricitinib, CFB change from
baseline, LS least squares, mTSS van der Heijde-modified total Sharp
score, MTX methotrexate, SDAI Simplified Disease Activity Index,
SDC smallest detectable change (1.4 in the RA-BEGIN-modified
intent-to-treat population)
Table 3 Odds of structural
damage progression for different
factors
Odds ratio Lower 95% CI Upper 95% CI p value
Baricitinib 4 mg vs MTX 0.57 0.31 1.04 0.066
Baricitinib 4 mg + MTX vs MTX 0.32 0.17 0.61 < 0.001
Age 1.00 0.98 1.02 0.820
Sex (female vs male) 2.28 1.17 4.44 0.015
Duration of RA 0.95 0.87 1.05 0.322
Baseline BMI 0.94 0.89 0.99 0.025
ACPA positive (vs negative) 1.19 0.42 3.41 0.745
RF positive (vs negative) 1.76 0.20 15.06 0.608
Smoker (yes vs no) 1.92 1.04 3.56 0.037
Baseline hsCRP 1.02 1.01 1.03 < 0.001
Baseline HAQ-DI 0.70 0.45 1.09 0.111
Baseline mTSS 1.00 0.99 1.02 0.319
Baseline CDAI 1.03 1.00 1.05 0.038
Baseline joint erosions (positive vs negative) 1.44 0.80 2.59 0.224
Odds ratios were estimated using a multivariate logistic regression model adjusted for baseline factors. Factors
significantly associated with an increased or decreased risk of structural damage progression are shown in bold
ACPA anti-citrullinated protein antibody, BMI body mass index, CDAI Clinical Disease Activity Index, CI
confidence interval,HAQ-DI Health Assessment Questionnaire-Disability Index, hsCRP high-sensitivity C-reac-
tive protein, mTSS van der Heijde-modified total Sharp score, MTX methotrexate, RA rheumatoid arthritis, RF
rheumatoid factor
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fact that female sex and smoking are known risk factors for
RA [25]. A number of other studies have investigated factors
associated with increased structural damage in early RA.
These included the presence of RF and/or anti-citrullinated
protein antibodies, low haemoglobin levels, decreased bone
mineral density, the presence of magnetic resonance imaging
bone marrow oedema, the presence of tumour necrosis
factor-α 308A allele with increased metalloproteinase 3 activ-
ity, female sex, and local joint swelling with or without ten-
derness at least once in the first 2 years of the disease [1,
26–31]. In addition, high BMI was associated with a lower
risk of structural damage progression [27].
However, in contrast to our findings, results of one study
suggested that male sex is associated with a higher risk of
structural damage progression [27], whereas another report
suggested there is no difference between the sexes in joint
damage [32]. A recent report questioned the association with
smoking, as the authors found no difference in joint damage
between smokers and non-smokers [33].
Our findings are limited in that the analyses were post hoc.
Nevertheless, we included data from a large number of pa-
tients and conducted multivariate analyses to control for po-
tential imbalances in baseline factors. Two measures of
sustained clinical improvement were used, and both analyses
produced similar findings.
In conclusion, although no formal statistical comparisons
were performed between treatments with respect to the pro-
portion of patients with structural damage progression based
on treatment response, our results indicate that patients with
active RA who achieved a sustained DAS28-hsCRP ≤ 3.2 or
SDAI score ≤ 11 with treatment are probably less likely to
experience structural damage progression than patients who
Fig. 3 Adjusted probability of
structural damage progression as
a function of (a) baseline hsCRP,
(b) baseline CDAI score, and (c)
baseline BMI, estimated using a
multivariate logistic regression
model. BMI body mass index,
CFB change from baseline, CDAI
Clinical Disease Activity Index,
hsCRP high-sensitivity C-reactive
protein, SDC smallest detectable
change (1.4 in the RA-BEGIN-
modified intent-to-treat
population)
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do not, independent of treatment. In patients with a sustained
DAS28-hsCRP ≤ 3.2 or SDAI score ≤ 11, structural damage
progression was more likely with MTX monotherapy than
with baricitinib, either as monotherapy or in combination with
MTX. In patients who did not achieve a sustained DAS28-
hsCRP ≤ 3.2 or SDAI score ≤ 11, structural damage progres-
sion was less likely with a combination of baricitinib plus
MTX than with MTX monotherapy. For these patients, the
clinician should consider alternative treatment to enable the
patient to achieve the recommended treatment goals of remis-
sion or low disease activity. Independent of treatment, base-
line factors significantly associated with increased risk of
structural damage progression included higher hsCRP and
CDAI score, smoking, female sex, and lower body mass
index.
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